Total Payments
$359,870
2024 Payments
$78,463
Companies
22
Transactions
297
Medicare Patients
2,185
Medicare Billing
$228,390
Payment Breakdown by Category
Other$191,226 (53.1%)
Consulting$137,096 (38.1%)
Travel$23,115 (6.4%)
Food & Beverage$8,276 (2.3%)
Research$152.39 (0.0%)
Education$3.85 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $137,096 | 43 | 38.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $75,456 | 21 | 21.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $62,660 | 17 | 17.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $28,300 | 8 | 7.9% |
| Honoraria | $24,810 | 10 | 6.9% |
| Travel and Lodging | $23,115 | 88 | 6.4% |
| Food and Beverage | $8,276 | 108 | 2.3% |
| Unspecified | $152.39 | 1 | 0.0% |
| Education | $3.85 | 1 | 0.0% |
Payments by Type
General
$359,718
296 transactions
Research
$152.39
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Intercept Pharmaceuticals, Inc. | $135,394 | 94 | $0 (2024) |
| Gilead Sciences, Inc. | $49,654 | 58 | $0 (2024) |
| ABBVIE INC. | $35,483 | 53 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $27,231 | 13 | $0 (2024) |
| GlaxoSmithKline, LLC. | $22,635 | 10 | $0 (2024) |
| Madrigal Pharmaceuticals | $19,540 | 18 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $16,105 | 9 | $0 (2017) |
| Siemens Medical Solutions USA, Inc. | $12,523 | 3 | $0 (2023) |
| Novo Nordisk Inc | $12,488 | 5 | $0 (2024) |
| Shionogi Inc | $8,672 | 7 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $78,463 | 55 | GlaxoSmithKline, LLC. ($22,482) |
| 2023 | $57,481 | 37 | INTERCEPT PHARMACEUTICALS, INC. ($43,049) |
| 2022 | $33,104 | 23 | INTERCEPT PHARMACEUTICALS, INC. ($19,814) |
| 2021 | $8,277 | 6 | Novo Nordisk Inc ($4,500) |
| 2020 | $7,650 | 3 | Novo Nordisk Inc ($5,250) |
| 2019 | $41,507 | 65 | Intercept Pharmaceuticals, Inc. ($12,089) |
| 2018 | $42,555 | 50 | Intercept Pharmaceuticals, Inc. ($14,777) |
| 2017 | $90,832 | 58 | Intercept Pharmaceuticals, Inc. ($33,296) |
All Payment Transactions
297 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/11/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $127.26 | General |
| Category: LIVER DISEASE | ||||||
| 12/04/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/04/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $137.07 | General |
| Category: LIVER DISEASE | ||||||
| 11/21/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,046.00 | General |
| Category: Rare Disease | ||||||
| 11/21/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $143.51 | General |
| Category: Rare Disease | ||||||
| 11/21/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Travel and Lodging | In-kind items and services | $44.22 | General |
| Category: Rare Disease | ||||||
| 11/18/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $146.97 | General |
| Category: LIVER DISEASE | ||||||
| 11/07/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,046.00 | General |
| Category: Rare Disease | ||||||
| 11/07/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Travel and Lodging | In-kind items and services | $130.11 | General |
| Category: Rare Disease | ||||||
| 11/04/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/04/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: LIVER DISEASE | ||||||
| 10/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.53 | General |
| 09/27/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $8,000.00 | General |
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,935.00 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $346.57 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $226.86 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $186.86 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $114.80 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $94.62 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $80.91 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $78.25 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $77.39 | General |
| Category: LIVER DISEASE | ||||||
| 09/26/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,046.00 | General |
| Category: Rare Disease | ||||||
| 09/26/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Travel and Lodging | In-kind items and services | $106.75 | General |
| Category: Rare Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EV | GlaxoSmithKline, LLC. | $152.39 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 469 | 572 | $197,478 | $40,336 |
| 2022 | 9 | 341 | 366 | $190,701 | $27,104 |
| 2021 | 11 | 698 | 852 | $464,921 | $86,237 |
| 2020 | 10 | 677 | 853 | $436,845 | $74,713 |
Total Patients
2,185
Total Services
2,643
Medicare Billing
$228,390
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 150 | 195 | $107,250 | $22,761 | 21.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 43 | 43 | $42,871 | $6,533 | 15.2% |
| 90739 | Hepatitis b vaccine (hepb), cpg-adjuvanted, adult dosage, 2 dose or 4 dose schedule, for intramuscular use | Office | 2023 | 18 | 27 | $11,664 | $4,193 | 35.9% |
| 91200 | Measurement of liver stiffness | Office | 2023 | 105 | 111 | $23,643 | $3,247 | 13.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 117 | 148 | $3,128 | $1,226 | 39.2% |
| G0010 | Administration of hepatitis b vaccine | Office | 2023 | 22 | 34 | $3,672 | $1,193 | 32.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 14 | 14 | $5,250 | $1,183 | 22.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 127 | 134 | $66,196 | $9,749 | 14.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 68 | 73 | $50,297 | $5,638 | 11.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 11 | $9,669 | $2,080 | 21.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 15 | 15 | $13,755 | $2,074 | 15.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 20 | 32 | $9,206 | $2,060 | 22.4% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 13 | 13 | $19,693 | $1,700 | 8.6% |
| 91200 | Measurement of liver stiffness | Office | 2022 | 65 | 65 | $12,480 | $1,572 | 12.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 11 | 12 | $2,700 | $1,255 | 46.5% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 11 | 11 | $6,705 | $975.69 | 14.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 237 | 333 | $158,175 | $37,977 | 24.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 104 | 116 | $44,428 | $9,910 | 22.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 49 | 52 | $33,332 | $8,912 | 26.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 32 | 33 | $29,007 | $6,328 | 21.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 45 | 84 | $27,048 | $5,637 | 20.8% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 28 | 29 | $59,247 | $5,024 | 8.5% |
| 91200 | Measuring the stiffness in the liver via elastography | Office | 2021 | 151 | 152 | $29,184 | $4,463 | 15.3% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 11 | 11 | $29,909 | $2,744 | 9.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 17 | 17 | $12,512 | $2,601 | 20.8% |
About Dr. David Bernstein, MD
Dr. David Bernstein, MD is a Gastroenterology healthcare provider based in Manhasset, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1912078304.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Bernstein, MD has received a total of $359,870 in payments from pharmaceutical and medical device companies, with $78,463 received in 2024. These payments were reported across 297 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($137,096).
As a Medicare-enrolled provider, Bernstein has provided services to 2,185 Medicare beneficiaries, totaling 2,643 services with total Medicare billing of $228,390. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Hepatology
- Location Manhasset, NY
- Active Since 11/10/2006
- Last Updated 09/13/2024
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1912078304
Products in Payments
- OCALIVA (Drug) $99,976
- OCA (Drug) $33,296
- IQIRVO (Drug) $20,734
- REZDIFFRA (Drug) $19,394
- Vemlidy (Drug) $17,497
- Viekira (Drug) $14,125
- Mavyret (Drug) $12,794
- Epclusa (Drug) $7,745
- ZEPATIER (Drug) $7,050
- Mulpleta (Drug) $4,150
- MAVYRET (Drug) $3,600
- GIVLARRI (Drug) $2,940
- XIFAXAN (Drug) $2,152
- Stivarga (Drug) $900.00
- CREON (Drug) $222.75
- Doptelet (Drug) $158.77
- RELISTOR (Drug) $158.03
- RESMETIROM (Drug) $146.97
- TERLIVAZ (Drug) $137.29
- Livmarli (Drug) $42.73
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Manhasset
Dr. Keith Sultan, Md, MD
Gastroenterology — Payments: $55,199
Gastroenterology $55,199
Dr. Calvin Lee, M.d, M.D
Gastroenterology — Payments: $1,152
Gastroenterology $1,152
Dr. Susan Ramdhaney, M.d, M.D
Gastroenterology — Payments: $908.59
Gastroenterology $908.59
Bernard Stark, Md, MD
Gastroenterology — Payments: $745.37
Gastroenterology $745.37
Edna Khodadadian, Md, MD
Gastroenterology — Payments: $716.43
Gastroenterology $716.43
Chun Kit Hung, Md, MD
Gastroenterology — Payments: $617.11
Gastroenterology $617.11